Literature DB >> 30362662

Internalized HIV stigma, ART initiation and HIV-1 RNA suppression in South Africa: exploring avoidant coping as a longitudinal mediator.

Valerie A Earnshaw1, Laura M Bogart2, Jean-Philippe Laurenceau3, Brian T Chan4,5, Brendan G Maughan-Brown6, Janan J Dietrich7, Ingrid Courtney8, Gugulethu Tshabalala7, Catherine Orrell8, Glenda E Gray7,9, David R Bangsberg10, Ingrid T Katz4,5,11,12.   

Abstract

INTRODUCTION: Cross-sectional evidence suggests that internalized HIV stigma is associated with lower likelihoods of antiretroviral therapy (ART) initiation and HIV-1 RNA suppression among people living with HIV (PLWH). This study examined these associations with longitudinal data spanning the first nine months following HIV diagnosis and explored whether avoidant coping mediates these associations.
METHODS: Longitudinal data were collected from 398 South African PLWH recruited from testing centres in 2014 to 2015. Self-report data, including internalized stigma and avoidant coping (denying and distracting oneself from stressors), were collected one week and three months following HIV diagnosis. ART initiation at six months and HIV-1 RNA at nine months were extracted from the South Africa National Health Laboratory Service database. Two path analyses were estimated, one testing associations between internalized stigma, avoidant coping and ART initiation, and the other testing associations between internalized stigma, avoidant coping and HIV-1 RNA suppression.
RESULTS: Participants were 36 years old, on average, and 63% identified as female, 18% as Zulu and 65% as Xhosa. The two path models fit the data well (ART initiation outcome: X2 (7) = 8.14, p = 0.32; root mean square error of approximation (RMSEA) = 0.02; comparative fit index (CFI) = 0.92; HIV-1 RNA suppression outcome: X2 (7)  = 6.58, p = 0.47; RMSEA = 0.00; CFI = 1.00). In both models, internalized stigma one week after diagnosis was associated with avoidant coping at three months, controlling for avoidant coping at one week. In turn, avoidant coping at three months was associated with lower likelihood of ART initiation at six months in the first model and lower likelihood of HIV-1 RNA suppression at nine months in the second model. Significant indirect effects were observed between internalized stigma with ART non-initiation and unsuppressed HIV-1 RNA via the mediator of avoidant coping.
CONCLUSIONS: Internalized stigma experienced soon after HIV diagnosis predicted lower likelihood of ART initiation and HIV-1 RNA suppression over the first year following HIV diagnosis. Avoidant coping played a role in these associations, suggesting that PLWH who internalize stigma engage in greater avoidant coping, which in turn worsens medication- and health-related outcomes. Interventions are needed to address internalized stigma and avoidant coping soon after HIV diagnosis to enhance treatment efforts during the first year after HIV diagnosis.
© 2018 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.

Entities:  

Keywords:  zzm321990HIVzzm321990; South Africa; antiretroviral therapy; coping; stigma

Mesh:

Substances:

Year:  2018        PMID: 30362662      PMCID: PMC6202800          DOI: 10.1002/jia2.25198

Source DB:  PubMed          Journal:  J Int AIDS Soc        ISSN: 1758-2652            Impact factor:   5.396


antiretroviral therapy cluster of differentiation 4 National Laboratory Service people living with HIV root mean square error of approximation Joint United Nations Programme on HIV/AIDS

Introduction

The Joint United Nations Programme on HIV/AIDS’ (UNAIDS) goals for addressing the HIV epidemic include that 95% of people who have been diagnosed with HIV will have initiated antiretroviral therapy (ART) and 95% of people receiving ART will have suppressed HIV‐1 RNA by 2030 1. Initiating ART is a key step in the treatment cascade and necessary to achieve HIV‐1 RNA suppression, which in turn extends the lives of people living with HIV (PLWH) and prevents the transmission of HIV to others 2, 3, 4, 5. Reaching the goals set by UNAIDS may be difficult in places like South Africa, where only 61% of 7.2 million PLWH were receiving ART and 47% had suppressed HIV‐1 RNA in 2017 6. HIV stigma has long been recognized as a barrier to treatment and physical health among PLWH in South Africa and globally 7, 8, 9; yet, the mediating mechanisms linking HIV stigma with treatment and physical health outcomes remain understudied using prospective longitudinal designs 10. The current study addresses this gap by exploring longitudinal associations between HIV stigma, coping, ART initiation and HIV‐1 RNA suppression among PLWH in South Africa. HIV stigma is conceptualized as a social process that exists when labelling, stereotyping, separation and discrimination of PLWH occur within a power structure 8. This social process, in turn, is experienced by individuals as a series of stigma mechanisms 11. Internalized stigma involves endorsing negative beliefs and feelings about PLWH and applying them to the self 11. Internalized stigma may be particularly high in the first few weeks after HIV diagnosis and then decreases over time 12. HIV stigma mechanisms are associated with lower likelihood of ART adherence 10, 13, and internalized HIV stigma appears to play a prominent role in treatment‐related behaviours. In a cross‐sectional study of PLWH in the United States, internalized stigma was associated with lower likelihood of ART adherence after controlling for enacted and anticipated stigma (i.e. past experiences of discrimination and future expectations of discrimination) 14. Other cross‐sectional studies in the United States and Canada have also found associations between internalized stigma and lower likelihood of ART adherence 15, 16 as well as ART initiation 17. Although generally understudied in longitudinal studies, one longitudinal study in the United States found no significant prospective association between internalized stigma and ART adherence one month later 18. No known longitudinal studies have examined the prospective association between internalized stigma and ART initiation. Internalized stigma may be associated with a lower likelihood of ART initiation, in part, because it compromises adaptive coping. Coping is the process of managing demands created by stressful events that are perceived as exceeding one's resources 19, 20. Receiving an HIV diagnosis and needing to initiate ART may be experienced as stressful events 21 that exceed one's psychological, social and/or financial resources 22. Coping processes can be adaptive, helping people to respond to stressors in positive or healthy ways (e.g. approach or problem‐focused coping), or maladaptive, leading people to respond to stressors in negative or unhealthy ways (e.g. avoidant coping) 20. Internalized stigma may lead to maladaptive coping in part because it undermines hope and self‐esteem 23. Maladaptive coping, in turn, undermines engagement in health behaviours: Avoidant coping is associated with lower medication adherence and higher HIV‐1 RNA among PLWH 24. We hypothesized that: (1) internalized stigma is associated with lower likelihoods of ART initiation and HIV‐1 RNA suppression over the first nine months post‐HIV diagnosis; and (2) maladaptive coping mediates these associations.

Methods

Context

The study took place between July 2014 and July 2015 in Soweto and Gugulethu, which are urban, densely populated townships in South Africa predominately inhabited by black South Africans. National estimates indicate a high prevalence of internalized stigma (43%) among PLWH in South Africa 9. In resource‐poor areas, internalized stigma may be particularly salient due to a strong interplay between socio‐economic inequalities and stigma, with higher socio‐economic status associated with lower internalized stigma 25. In an urban, resource‐poor area of Cape Town, 58% of patients referred for HIV treatment by a mobile clinic reported feeling either guilty of ashamed that they have HIV 26. Individuals were recruited from HIV testing centres for this study. At one site in Soweto, the testing centre was part of a research unit. Otherwise, testing centres were housed within community health centres wherein they were integrated with other care (e.g. primary care, HIV treatment).

Participants

Individuals were tested for HIV and immediately given their results. Those who tested positive had blood drawn for a CD4 count and were advised to return a week later for results. Participants included 500 ART‐eligible adults (18 years or older) who were recruited as they received their CD4 count results. ART eligibility was determined based on South African guidelines (CD4+ ≤ 350 cells/mm3 before 1 January 2015 and CD4+ < 500 cells/mm3 after 1 January 2015). Children and pregnant women were excluded from participating because they qualified for intensive adherence support.

Procedures

Trained multilingual interviewers, who were independent from the clinical staff, delivered an in‐person survey using Research Electronic Data Capture (REDCap) 27. Self‐report data, including internalized stigma and coping, were collected from participants one week following their HIV diagnosis and three months later. Medical data, including ART initiation and HIV‐1 RNA, were extracted from the National Health Laboratory Service (NHLS) database at six and nine months post‐baseline by a study team member. NHLS provides laboratory services to all public‐sector facilities in South Africa. Study procedures received Institutional Review Board approval from Human Subjects Committees at Partners Healthcare, the University of Witwatersrand Ethics Committee, the Gauteng Department of Health and the University of Cape Town Ethics Committee, and all participants provided informed consent.

Measures

Internalized HIV stigma was measured with the Internalized AIDS‐Related Stigma Scale 28. Other experiences of stigma, such as enacted and anticipated stigma, were not measured. The Internalized AIDS‐Related Stigma Scale asks participants whether they “agree” (1) or “disagree” (0) with six statements. Results of an exploratory factor analysis using the baseline data suggested a two‐factor solution accounting for 69.25% of the variance in the scale. The first factor included four internalized stigma items capturing feelings of shame, worthlessness, guilt and dirty, and the second factor included two disclosure concerns items. The disclosure items were therefore dropped from the scale. The remaining internalized stigma subscale had adequate reliability (Cronbach's alpha = 0.81), and a mean composite score was created to represent internalized stigma. Maladaptive coping was measured with 12 items from the Brief COPE measuring self‐distraction, denial, substance use, disengagement, venting and self‐blame 29. Items from the self‐blame subscale regarding self‐criticism and self‐blame that conceptually overlapped with internalized stigma were first removed. An initial factor analysis suggested a three‐factor solution accounting for 62.34% of the variance in the scale; however, it included one item that did not load well onto any subscale (“I've been saying to myself ‘this isn't real’”; factor loadings < 0.40). After this item was deleted, an additional factor analysis was conducted that suggested a two‐factor solution accounting for 54.50% of the variance in the scale. One factor included six items related to avoidance, denial and negative emotion release. This avoidance subscale had adequate reliability (Cronbach's alpha = 0.76). A mean composite score was created to represent the construct. Following previously validated procedures for imputing dates of treatment initiation using NHLS data 30, ART initiation by six months was determined based on a measure of creatinine. Plasma RNA results were directly entered into NHLS by clinical providers, and HIV‐1 RNA suppression by nine months was calculated (<50 copies/mL). Participants reported their age, sex, ethnicity, relationship status, education and employment at the baseline study interview. They also reported their binge drinking (calculated from number of drinks per day), recreational drug use and tobacco use in the past 30 days.

Analyses

First, descriptive analyses were conducted using SPSS 31 to characterize the socio‐demographic and other relevant characteristics of the sample. Second, all correlations between internalized stigma at one week after HIV diagnosis, avoidant coping at three months, ART initiation at six months and HIV‐1 RNA suppression at nine months were examined. Correlations between socio‐demographic characteristics and these variables were also explored. Pearson's correlations were used for correlations between continuous variables, point‐biserial between continuous and dichotomous variables, and Spearman's rho between dichotomous variables. Third, two path analyses were conducted using Mplus version 8 32 to test for longitudinal mediation 33. The first model included ART initiation as the dependent variable, and the second model included HIV‐1 RNA suppression as the dependent variable. Associations between internalized stigma at one week post‐diagnosis with avoidant coping at three months post‐diagnosis were modelled following recommendations for longitudinal analyses by controlling for avoidant coping at one week 34. Associations between avoidant coping at three months with ART initiation at six months post‐diagnosis and HIV‐1 RNA suppression at nine months post‐diagnosis were also modelled. The effects of socio‐demographic characteristics and substance use that were correlated with the mediator (avoidant coping) and/or outcomes (ART initiation and HIV‐1 RNA suppression) were controlled for on both the mediator and outcomes, and models controlled for clustering by study site via standard error adjustment using a sandwich estimator. Socio‐demographic characteristics and substance use variables that were not statistically significant in the multivariate path analyses were trimmed from the final model 35. Following recommendations for mediation testing with dichotomous outcomes 36, 37, 38, counterfactually based indirect effects for links between baseline internalized HIV stigma and the distal outcomes ART initiation and HIV‐1 RNA suppression via the mediator of three‐month avoidant coping were estimated.

Results

Of the 500 participants enrolled in the study, 14 (2.8%) did not respond to one of the substance use questions at baseline and an additional 88 (18.5%) did not complete the three‐month survey. These 102 individuals with missing data were excluded from the analyses, resulting in an analytic sample of 398 participants. Sample characteristics, including socio‐demographic data, are displayed in Table 1 and reflected those of patients at the data collection sites. Participants who did not identify as Zulu or Xhosa identified as Sesotho (5.8%), Tsonga (2.3%) or another ethnicity (e.g. Tswanga, Venda, N. Sotho). Fewer participants who were single (17.6%; X (1) = 5.69, p = 0.02) or virally suppressed (14.7%; X (1) = 7.24; p = 0.01) were excluded from the analytic sample than those who were included. Conversely, more engaged in recreational drug use (18.6%; X (1) = 36.23, p < 0.01).
Table 1

Sample characteristics (n = 398)

Mean (SD)% (n)
Socio‐demographic characteristics
Age36.11 (9.24)
Female63.3 (252)
Zulu ethnicity17.6 (70)
Xhosa ethnicity64.6 (257)
Single relationship status70.6 (281)
High school education26.1 (104)
Employed43.5 (173)
Recreational drug use2.8 (11)
Binge drinking46.2 (184)
Tobacco use24.4 (97)
Internalized stigma, 1 week0.26 (0.34)46.5 (185)
Avoidant coping
1 week1.60 (0.68)
3 months1.32 (0.55)
ART initiation, 6 months57.3 (228)
HIV‐1 RNA suppression, 9 months27.6 (110)

Internalized stigma scores ranged 0 to 1 and coping scores ranged 1 to 4. The mean internalized stigma score and percentage of participants who agreed with at least one internalized stigma item are reported.

ART, antiretroviral therapy.

Sample characteristics (n = 398) Internalized stigma scores ranged 0 to 1 and coping scores ranged 1 to 4. The mean internalized stigma score and percentage of participants who agreed with at least one internalized stigma item are reported. ART, antiretroviral therapy. As shown in Table 2, internalized stigma at one week after HIV diagnosis was positively correlated with avoidant coping at three months. Avoidant coping was negatively correlated with ART initiation at six months and HIV‐1 RNA suppression at nine months.
Table 2

Longitudinal correlations

Internalized stigma, 1 weekAvoidant coping, 3 monthsART initiation, 6 monthsHIV‐1 RNA suppression, 9 months
Avoidant coping, 3 months0.23** 1
ART initiation, 6 months−0.03−0.10* 1
HIV‐1 RNA suppression, 9 months0.02−0.13** 0.53** 1
Age−0.05−0.010.080.04
Female−0.01−0.010.050.04
Zulu ethnicity0.070.33** −0.11* −0.09
Xhosa ethnicity−0.22** −0.48** 0.14** 0.13*
Single relationship status−0.01−0.01−0.06−0.10
High school education−0.05−0.20** 0.040.05
Employed0.01−0.06−0.010.01
Recreational drug use0.11* 0.17** −0.04−0.04
Binge drinking−0.02−0.01−0.01−0.03
Tobacco use−0.06−0.05−0.04−0.01

**p < 0.01, *p < 0.05.

ART, antiretroviral therapy.

Longitudinal correlations **p < 0.01, *p < 0.05. ART, antiretroviral therapy. The first model, predicting ART initiation at 6 months, demonstrated good fit to the data (X 2(7) = 8.14, p = 0.32; RMSEA = 0.02 (90% CI = 0.00 to 0.07); comparative fit index (CFI) = 0.92). As shown in Figure 1, internalized stigma at one week was associated with avoidant coping at three months. Avoidant coping at three months was associated with lower likelihood of ART initiation at six months. Additionally, participants who were not Xhosa (B(SE) = −0.31(0.13), p = 0.01) engaged in more avoidant coping. The remaining socio‐demographic variables and substance use variables were not associated with avoidant coping or ART initiation. A significant counterfactually based indirect effect of internalized stigma on ART initiation via avoidant coping was also observed (total natural indirect effect: OR = 1.04, p = 0.04).
Figure 1

Longitudinal structural equation model of associations between internalized stigma, avoidant coping and antiretroviral therapy initiation.

Values are unstandardized regression coefficients. Model controls for socio‐demographics and substance use on avoidant coping at three months and ART initiation at six months. **p < 0.01

Longitudinal structural equation model of associations between internalized stigma, avoidant coping and antiretroviral therapy initiation. Values are unstandardized regression coefficients. Model controls for socio‐demographics and substance use on avoidant coping at three months and ART initiation at six months. **p < 0.01 The second model, predicting HIV‐1 RNA suppression at 9 months, also demonstrated good fit to the data (X 2(7)  = 6.58, p = 0.47; RMSEA = 0.00 (90% CI = 0.00 to 0.06); CFI = 1.00). As shown in Figure 2, internalized stigma at one week was again associated with avoidant coping at three months. Avoidant coping at three months was associated with lower likelihood of HIV‐1 RNA suppression at nine months. Additionally, participants who were not Xhosa, engaged in more avoidant coping (B(SE) = −0.34(0.13), p = 0.01). The remaining socio‐demographic variables and substance use were not associated with avoidant coping or HIV‐1 RNA suppression in this model. A significant counterfactually based indirect effect of internalized stigma on HIV‐1 RNA suppression via avoidant coping was also observed (total natural indirect effect: OR = 1.07, p < 0.01).
Figure 2

Longitudinal structural equation model of associations between internalized stigma, avoidant coping and HIV‐1 RNA suppression.

Values are unstandardized regression coefficients. Model controls for socio‐demographics and substance use on avoidant coping at three months and HIV‐1 RNA suppression and nine months. **p < 0.01

Longitudinal structural equation model of associations between internalized stigma, avoidant coping and HIV‐1 RNA suppression. Values are unstandardized regression coefficients. Model controls for socio‐demographics and substance use on avoidant coping at three months and HIV‐1 RNA suppression and nine months. **p < 0.01

Discussion

Results of this longitudinal study of 398 South African PLWH contribute to understanding of whether and how internalized HIV stigma is associated with deleterious HIV treatment and physical health outcomes. Previous cross‐sectional work has suggested that internalized HIV stigma is associated with a lower likelihood of ART initiation 17. The current study extends this research by demonstrating that internalized stigma measured one week after HIV diagnosis is prospectively associated with both non‐initiation of ART at six months as well as unsuppressed HIV‐1 RNA at nine months. The associations between internalized stigma and these outcomes were mediated, and results reflected inconsistent mediation (i.e. the signs of the mediated effect were opposite of the signs of the direct effects) 38. In cases of inconsistent mediation, the direct effect between an independent variable and dependent variable is non‐significant despite the existence of a significant indirect effect between the variables 38. In the current study, the direct effects between internalized stigma with ART initiation and HIV‐1 RNA suppression were non‐significant despite the existence of significant indirect effects between these variables. One previous longitudinal study did not find a direct association between internalized stigma and ART adherence 18. This non‐significant finding may have also been due to inconsistent mediation (i.e. internalized stigma may have been associated with ART adherence in this previous study via an untested mediator) or differences in the dependent variables (i.e. internalized stigma may play different roles in ART initiation vs. adherence). Our results further suggest that maladaptive coping mediates associations between internalized HIV stigma with ART initiation and HIV‐1 RNA suppression. Internalized HIV stigma may lead PLWH to engage in efforts to avoid, deny and distract themselves from stressors, which in turn reduces the likelihood of ART initiation and HIV‐1 RNA suppression. Previous cross‐sectional studies have identified depressive symptoms, loneliness, low perceived social support, attachment‐related anxiety and HIV disclosure concerns as mediators of associations between internalized HIV stigma and ART‐related outcomes, including initiation and adherence 15, 16, 17. It is possible that the process linking internalized HIV stigma with ART initiation and HIV‐1 RNA involves serial mediation of these psychosocial variables. For example, internalized HIV stigma may lead to greater depressive symptoms, which in turn may lead to greater avoidant coping, ART non‐initiation and unsuppressed HIV‐1 RNA. The process linking internalized HIV stigma with ART non‐initiation and HIV‐1 RNA non‐suppression may also involve multiple pathways. Future research exploring multiple psychosocial mediators simultaneously can contribute to stronger understanding of the mechanisms linking internalized HIV stigma with HIV treatment and health outcomes.

Strengths, limitations and future directions

These results add to the literature on associations between internalized HIV stigma with treatment and physical health outcomes. Much of the previous research examining these associations has been cross‐sectional 14, 15, 17, limiting possibilities for forming firm conclusions regarding prospective associations between variables. The current study answers a call for longitudinal research testing prospective associations between stigma and ART outcomes, and for identifying mediators of these associations 10. Results of this longitudinal study suggest that internalized HIV stigma one week after HIV diagnosis is associated with avoidant coping at three months, controlling for avoidant coping one week after HIV diagnosis. Moreover, results suggest that internalized stigma one week after HIV diagnosis is associated with lower likelihoods of ART initiation at six months and HIV‐1 RNA suppression at nine months. Direct effects between internalized stigma with ART initiation and HIV‐1 RNA suppression were not statistically significant, but indirect effects reflecting inconsistent mediation were observed. Future researchers examining associations between internalized stigma with similar outcomes should note that indirect effects may exist between these variables even if direct effects are not statistically significant, and therefore, it may be important to explore mediators to fully understand these associations. The current study focused on the role of internalized HIV stigma in treatment and physical health outcomes. Other studies have focused on other HIV stigma mechanisms, including enacted and/or anticipated stigma 13, 39. Future research that includes multiple HIV stigma mechanisms can contribute to our understanding of which stigma mechanisms are the most robust predictors of HIV treatment and health outcomes. Additionally, participants may experience stigma associated with other socially devalued characteristics (e.g. race, gender). Future longitudinal research should examine the extent to which and mechanisms whereby these other forms of stigma are associated with HIV treatment and physical health outcomes. Future research may also include measures of resilience resources, such as adaptive coping strategies and social support, to provide insight into who is resilient to the deleterious effects of HIV stigma. ART initiation by six months after HIV diagnosis was abstracted from South Africa's NHLS. Participants may have initiated ART before six months. Prior research focused on associations between ART initiation and subsequent changes in internalized HIV stigma 40 suggest that ART initiation may lead to decreases in internalized HIV stigma. Future studies incorporating more precise data on when ART is initiated can continue to clarify temporal associations between stigma, coping and ART initiation. Future work should measure ART adherence in addition to ART initiation and HIV‐1 RNA to further elucidate associations between internalized stigma, coping and these outcomes. Participants who provided incomplete data were excluded from the analyses. Fewer single and virally suppressed participants provided incomplete data than those who were included in the analyses, and more engaged in recreational drug use. Future research is needed to examine the extent to which findings generalize to participants who were underrepresented in the current analysis. Finally, it is important to study these associations within South Africa given findings suggesting that over 40% of the 7.2 million PLWH living in South Africa have internalized some degree of stigma, 39% are not currently receiving ART and 53% have unsuppressed HIV‐1 RNA 6, 9. Yet, future research is needed to determine whether these findings generalize to other sociocultural contexts.

Conclusions

Greater understanding of the role of internalized stigma in HIV treatment and physical health outcomes, including the mechanisms linking stigma with these outcomes, can inform intervention efforts to promote the wellbeing of PLWH. The current study suggests that it may be important to address internalized HIV stigma and maladaptive coping among individual PLWH to promote ART initiation and HIV‐1 RNA suppression. There is some evidence to suggest that livelihood interventions that enhance economic empowerment may reduce internalized HIV stigma, possibly by weakening symbolic associations between HIV and economic incapacity, illness and death 41, 42. Interventions that focus on other forms of empowerment, such as pride, may further reduce internalized stigma 43. It may also be possible to teach or strengthen adaptive coping strategies (e.g. support seeking) and decrease use of maladaptive coping strategies (e.g. avoidance and denial). Interventions involving coping effectiveness training and teaching cognitive behavioural stress management techniques have led to improved psychosocial outcomes, including reduced stress, among PLWH 20, 44. It may be particularly important to assess and address internalized stigma and coping strategies soon after HIV diagnosis to facilitate timely initiation of ART. Ultimately, it is important to eliminate HIV stigma so that no individual person diagnosed with HIV is at risk of internalizing HIV stigma and experiencing the negative downstream effects of internalized HIV stigma on diminished coping, ART non‐initiation and unsuppressed HIV‐1 RNA. Researchers, clinicians and policymakers should continue to develop and evaluate strategies to address HIV stigma and promote the wellbeing of PLWH in South Africa and globally.

Competing Interests

The authors have no competing interests.

Authors’ Contributions

VAE conceptualized, conducted and interpreted the data analyses with contributions from LMB, JPL, BTC, BGMB and ITK. VAE wrote the first draft of the manuscript. ITK designed and led the study with guidance and oversight from LMB, JJD, IC, GT, CO, GEG and DRB. All authors assisted with the writing and revising of the manuscript, provided final approval of the version to be published and agreed to be accountable for all aspects of the work.
  32 in total

Review 1.  The Association of HIV-Related Stigma to HIV Medication Adherence: A Systematic Review and Synthesis of the Literature.

Authors:  Shannon M Sweeney; Peter A Vanable
Journal:  AIDS Behav       Date:  2016-01

2.  Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.

Authors:  Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde
Journal:  J Biomed Inform       Date:  2008-09-30       Impact factor: 6.317

3.  The stressors and stress of being HIV-positive.

Authors:  S C Thompson; C Nanni; A Levine
Journal:  AIDS Care       Date:  1996-02

4.  Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.

Authors:  Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton
Journal:  N Engl J Med       Date:  2015-07-20       Impact factor: 91.245

5.  A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.

Authors:  Christine Danel; Raoul Moh; Delphine Gabillard; Anani Badje; Jérôme Le Carrou; Timothée Ouassa; Eric Ouattara; Amani Anzian; Jean-Baptiste Ntakpé; Albert Minga; Gérard M Kouame; Franck Bouhoussou; Arlette Emieme; Antoine Kouamé; André Inwoley; Thomas-d'Aquin Toni; Hugues Ahiboh; Mathieu Kabran; Cyprien Rabe; Baba Sidibé; Gustave Nzunetu; Romuald Konan; Joachim Gnokoro; Patrice Gouesse; Eugène Messou; Lambert Dohoun; Synali Kamagate; Abo Yao; Solange Amon; Amadou-Barenson Kouame; Aboli Koua; Emmanuel Kouamé; Yao Ndri; Olivier Ba-Gomis; Marcelle Daligou; Simplice Ackoundzé; Denise Hawerlander; Alex Ani; Fassery Dembélé; Fatoumata Koné; Calixte Guéhi; Constance Kanga; Serge Koule; Jonas Séri; Mykayila Oyebi; Nathalie Mbakop; Olewole Makaila; Carole Babatunde; Nathanael Babatounde; Gisèle Bleoué; Mireille Tchoutedjem; Alain-Claude Kouadio; Ghislaine Sena; Sahinou-Yediga Yededji; Rodrigue Assi; Alima Bakayoko; Alassane Mahassadi; Alain Attia; Armel Oussou; Max Mobio; Doféré Bamba; Mesmin Koman; Apollinaire Horo; Nina Deschamps; Henri Chenal; Madeleine Sassan-Morokro; Seidou Konate; Kakou Aka; Eba Aoussi; Valérie Journot; Célestin Nchot; Sophie Karcher; Marie-Laure Chaix; Christine Rouzioux; Papa-Salif Sow; Christian Perronne; Pierre-Marie Girard; Hervé Menan; Emmanuel Bissagnene; Auguste Kadio; Virginie Ettiegne-Traore; Corinne Moh-Semdé; Abo Kouame; Jean-Marie Massumbuko; Geneviève Chêne; Mireille Dosso; Serge K Domoua; Thérèse N'Dri-Yoman; Roger Salamon; Serge P Eholié; Xavier Anglaret
Journal:  N Engl J Med       Date:  2015-07-20       Impact factor: 91.245

6.  Socioeconomic gradients in internalized stigma among 4,314 persons with HIV in sub-Saharan Africa.

Authors:  Alexander C Tsai
Journal:  AIDS Behav       Date:  2015-02

7.  Measuring AIDS stigmas in people living with HIV/AIDS: the Internalized AIDS-Related Stigma Scale.

Authors:  Seth C Kalichman; Leickness C Simbayi; Allanise Cloete; Phumelele P Mthembu; Ruth N Mkhonta; Themba Ginindza
Journal:  AIDS Care       Date:  2009-01

8.  Pathways From HIV-Related Stigma to Antiretroviral Therapy Measures in the HIV Care Cascade for Women Living With HIV in Canada.

Authors:  Carmen H Logie; Ashley Lacombe-Duncan; Ying Wang; Angela Kaida; Tracey Conway; Kath Webster; Alexandra de Pokomandy; Mona R Loutfy; Aranka Anema; Denise Becker; Lori Brotto; Allison Carter; Claudette Cardinal; Guillaume Colley; Erin Ding; Janice Duddy; Nada Gataric; Robert S Hogg; Terry Hosward; Shahab Jabbari; Evin Jones; Mary Kestler; Andrea Langlois; Viviane Lima; Elisa Lloyd-Smith; Melissa Medjuck; Cari Miller; Deborah Money; Valerie Nicholson; Gina Ogilvie; Sophie Patterson; Neora Pick; Eric Roth; Kate Salters; Margarite Sanchez; Jacquie Sas; Paul Sereda; Marcie Summers; Christina Tom; Lu Wang; Kath Webster; Wendy Zhang; Rahma Abdul-Noor; Jonathan Angel; Fatimatou Barry; Greta Bauer; Kerrigan Beaver; Anita Benoit; Breklyn Bertozzi; Sheila Borton; Tammy Bourque; Jason Brophy; Ann Burchell; Allison Carlson; Lynne Cioppa; Jeffrey Cohen; Tracey Conway; Curtis Cooper; Jasmine Cotnam; Janette Cousineau; Annette Fraleigh; Brenda Gagnier; Claudine Gasingirwa; Saara Greene; Trevor Hart; Shazia Islam; Charu Kaushic; Logan Kennedy; Desiree Kerr; Maxime Kiboyogo; Gladys Kwaramba; Lynne Leonard; Johanna Lewis; Carmen Logie; Shari Margolese; Marvelous Muchenje; Mary Ndungʼu; Kelly OʼBrien; Charlene Ouellette; Jeff Powis; Corinna Quan; Janet Raboud; Anita Rachlis; Edward Ralph; Sean Rourke; Sergio Rueda; Roger Sandre; Fiona Smaill; Stephanie Smith; Tsitsi Tigere; Wangari Tharao; Sharon Walmsley; Wendy Wobeser; Jessica Yee; Mark Yudin; Jean-Guy Baril; Nora Butler Burke; Pierrette Clément; Janice Dayle; Danièle Dubuc; Mylène Fernet; Danielle Groleau; Aurélie Hot; Marina Klein; Carrie Martin; Lyne Massie; Brigitte Ménard; Nadia OʼBrien; Joanne Otis; Doris Peltier; Alie Pierre; Karène Proulx-Boucher; Danielle Rouleau; Édénia Savoie; Cécile Tremblay; Benoit Trottier; Sylvie Trottier; Christos Tsoukas; Jacqueline Gahagan; Catherine Hankins; Renee Masching; Susanna Ogunnaike-Cooke
Journal:  J Acquir Immune Defic Syndr       Date:  2018-02-01       Impact factor: 3.731

9.  Pathways between internalized stigma and outcomes related to recovery in schizophrenia spectrum disorders.

Authors:  Philip T Yanos; David Roe; Keith Markus; Paul H Lysaker
Journal:  Psychiatr Serv       Date:  2008-12       Impact factor: 4.157

Review 10.  Impact of HIV-related stigma on treatment adherence: systematic review and meta-synthesis.

Authors:  Ingrid T Katz; Annemarie E Ryu; Afiachukwu G Onuegbu; Christina Psaros; Sheri D Weiser; David R Bangsberg; Alexander C Tsai
Journal:  J Int AIDS Soc       Date:  2013-11-13       Impact factor: 5.396

View more
  25 in total

Review 1.  ART Adherence Among Men Who Have Sex with Men Living with HIV: Key Challenges and Opportunities.

Authors:  Katherine G Quinn; Dexter R Voisin
Journal:  Curr HIV/AIDS Rep       Date:  2020-08       Impact factor: 5.071

2.  HIV treatment cascade for older adults in rural South Africa.

Authors:  Julia K Rohr; Jennifer Manne-Goehler; Francesc Xavier Gómez-Olivé; Ryan G Wagner; Molly Rosenberg; Pascal Geldsetzer; Chodziwadziwa Kabudula; Kathleen Kahn; Stephen Tollman; Till Bärnighausen; Joshua A Salomon
Journal:  Sex Transm Infect       Date:  2019-06-26       Impact factor: 3.519

3.  Stigma and ART initiation among people with HIV and a lifetime history of illicit drug use in Saint-Petersburg, Russia-A prospective cohort analysis.

Authors:  Marina Vetrova; Sara Lodi; Lindsey Rateau; Gregory Patts; Elena Blokhina; Vladimir Palatkin; Tatiana Yaroslavtseva; Olga Toussova; Natalia Bushara; Sally Bendiks; Natalia Gnatienko; Evgeny Krupitsky; Dmitry Lioznov; Jeffrey H Samet; Karsten Lunze
Journal:  Int J Drug Policy       Date:  2022-02-05

4.  Understanding Repeat Positive HIV Testing in South Africa Under Changing Treatment Guidelines.

Authors:  Maria F Nardell; Bethany Hedt-Gauthier; Valerie A Earnshaw; Laura M Bogart; Janan J Dietrich; Ingrid Courtney; Gugulethu Tshabalala; Jacob Bor; Catherine Orrell; Glenda Gray; David R Bangsberg; Ingrid T Katz
Journal:  AIDS Behav       Date:  2021-10-27

5.  HIV Stigma, Depressive Symptoms, and Substance Use.

Authors:  Valerie A Earnshaw; Lisa A Eaton; Zachary K Collier; Ryan J Watson; Jessica L Maksut; Katherine B Rucinski; John F Kelly; Seth C Kalichman
Journal:  AIDS Patient Care STDS       Date:  2020-06       Impact factor: 5.078

6.  Cumulative Effects of Stigma Experiences on Retention in HIV Care Among Men and Women in the Rural Southeastern United States.

Authors:  Seth C Kalichman; Harold Katner; Ellen Banas; Marnie Hill; Moira O Kalichman
Journal:  AIDS Patient Care STDS       Date:  2020-11       Impact factor: 5.078

7.  Medical Mistrust and Stigma Associated with COVID-19 Among People Living with HIV in South Africa.

Authors:  Jana Jarolimova; Joyce Yan; Sabina Govere; Nompumelelo Ngobese; Zinhle M Shazi; Anele R Khumalo; Bridget A Bunda; Nafisa J Wara; Danielle Zionts; Hilary Thulare; Robert A Parker; Laura M Bogart; Ingrid V Bassett
Journal:  AIDS Behav       Date:  2021-05-17

8.  Intersectional Stigma Among People Transitioning From Incarceration to Community-Based HIV Care in Gauteng Province, South Africa.

Authors:  Daniel M Woznica; Nasiphi Ntombela; Christopher J Hoffmann; Tonderai Mabuto; Michelle R Kaufman; Sarah M Murray; Jill Owczarzak
Journal:  AIDS Educ Prev       Date:  2021-06

9.  Trajectories of HIV-related internalized stigma and disclosure concerns among ART initiators and non-initiators in South Africa.

Authors:  Brian T Chan; Brendan G Maughan-Brown; Laura M Bogart; Valerie A Earnshaw; Gugulethu Tshabalala; Ingrid Courtney; Janan J Dietrich; Catherine Orrell; Glenda E Gray; David R Bangsberg; Alexander C Tsai; Ingrid T Katz
Journal:  Stigma Health       Date:  2019-01-28

10.  The Treatment Ambassador Program: A Highly Acceptable and Feasible Community-Based Peer Intervention for South Africans Living with HIV Who Delay or Discontinue Antiretroviral Therapy.

Authors:  Catherine Orrell; Kathy Goggin; Ingrid T Katz; Laura M Bogart; Garrett M Fitzmaurice; Vincent S Staggs; Marya V Gwadz; Ingrid V Bassett; Anna Cross; Ingrid Courtney; Lungiswa Tsolekile; Regina Panda; Sonja Steck; David R Bangsberg
Journal:  AIDS Behav       Date:  2020-10-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.